Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Pelthos Therapeutics Inc (PTHS)

Pelthos Therapeutics Inc (PTHS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Pelthos Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference GlobeNewswire - Thu May 28, 4:00PM CDT

DURHAM, N.C., May 28, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient...

PTHS : 26.90 (+2.28%)
MarketBeat.com
Pelthos Therapeutics Q1 Earnings Call Highlights MarketBeat - Fri May 15, 7:12PM CDT

Pelthos Therapeutics (NYSEAMERICAN:PTHS) reported higher first-quarter revenue as prescriptions for its lead product, ZELSUVMI, continued to grow in the treatment’s third full quarter since launch, executives...

PTHS : 26.90 (+2.28%)
Pelthos Therapeutics Announces First Quarter 2026 Financial Results GlobeNewswire - Thu May 14, 6:00AM CDT

 ZELSUVMI ® net product revenue grew 17% quarter over quarter from $9.1 million in the fourth quarter of 2025 to $10.7 million in the first quarter of 2026 7,884 ZELSUVMI units prescribed by...

PTHS : 26.90 (+2.28%)
Pelthos Therapeutics to Report First Quarter 2026 Financial Results on May 14, 2026 GlobeNewswire - Fri May 1, 7:30AM CDT

DURHAM, N.C., May 01, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient...

PTHS : 26.90 (+2.28%)
Pelthos Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium GlobeNewswire - Tue Apr 14, 7:30AM CDT

DURHAM, N.C., April 14, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient...

PTHS : 26.90 (+2.28%)
Pelthos Therapeutics Announces CFO Transition GlobeNewswire - Fri Apr 10, 4:00PM CDT

DURHAM, N.C., April 10, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient...

PTHS : 26.90 (+2.28%)
Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain GlobeNewswire - Tue Mar 31, 7:30AM CDT

First clinical trial conducted in human subjects to evaluate CT2000 for the treatment of both acute ocular pain and chronic ocular surface pain commonly associated with dry eye disease CT2000 is a...

PTHS : 26.90 (+2.28%)
Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results GlobeNewswire - Thu Mar 19, 5:30AM CDT

ZELSUVMI ™ net product revenue grew 28% Quarter over Quarter to $9.1 million, bringing total ZELSUVMI net product revenue to $16.2 million, for the period from the launch in July 2025 through December...

PTHS : 26.90 (+2.28%)
Pelthos Therapeutics to Present at 38th Annual ROTH Conference GlobeNewswire - Thu Mar 12, 7:30AM CDT

DURHAM, N.C., March 12, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient...

PTHS : 26.90 (+2.28%)
Pelthos Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026 GlobeNewswire - Mon Mar 9, 7:30AM CDT

DURHAM, N.C., March 09, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient...

PTHS : 26.90 (+2.28%)

Barchart Exclusives

Intel Stock Has Risen Sixfold from Its 2025 Lows, but Don’t Expect a Dividend Yet Barchart - Tue Jun 9, 6:30PM CDT
INTC's reversal of fortunes has been a huge boon to investors, but with capex spending still expected to remain high and customers' cash slow to accumulate, don't expect Intel to reinstate its dividend anytime soon. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.